Marker Therapeutics is trading at $1.31, up 5.65%; its recently highlighted expanded manufacturing infrastructure for MT-601 is the most relevant company-specific development, though its role in the move is unconfirmed.
- Cellipont Bioservices and Kincell Bio combined to form Kincellis Advanced Therapies.
- The combined organization has approximately 140,000 square feet and 16 GMP suites.
- No source directly confirms the announcement caused the September 24, 2026 move; broader biotechnology shares are declining.